CTNNB1 and neuroendocrine carcinoma: PIK3CA variant was identified with VAF 82.8% in NEC, 75.2% in endometrioid carcinoma, 37.2% in ovarian endometriosis, and 77.2% in uterine EAH, while CTNNB1 variant was identified with VAF 76.9% in NEC, 64.6% in endometrioid carcinoma, 16.3% in ovarian endometriosis, and 68.7% in uterine EAH (Fig. 3).